Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203239 · ClinicalTrials.gov registry record · NA
Red Light Treatment in Peripheral Artery Disease
A NA study of Peripheral Artery Disease and Vasodilation, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03203239: Recruiting NA study of Peripheral Artery Disease and Vasodilation, sponsored by University of Alabama at Birmingham.
NCT03203239 is a NA study of Peripheral Artery Disease and Vasodilation that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03203239, a NA study of Peripheral Artery Disease and Vasodilation, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\<.9 or \>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.
Primary Outcome
Video intensity units from contrast images will be converted to ml/min/g tissue
Conditions Studied
Interventions
- DEVICE Red Light (670 nm energy)
- DRUG Octafluoropropane
Study Locations (1)
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT03203239 shows while recruiting
NCT03203239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (68% lower).
The record links to 3 conditions, with Peripheral Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Red Light (670 nm energy) is the first listed.
NCT03203239 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03203239 about?
NCT03203239 is a clinical study titled "Red Light Treatment in Peripheral Artery Disease". Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\<.9 or \>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquis...
What is the current status of trial NCT03203239?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2018-01-17. Estimated completion is 2027-12-31.
What conditions does trial NCT03203239 study?
This clinical trial studies the following conditions: Peripheral Artery Disease, Vasodilation, Claudication, Intermittent.
What interventions are being tested in trial NCT03203239?
The interventions under investigation include: Red Light (670 nm energy) (DEVICE), Octafluoropropane (DRUG).
Who is sponsoring clinical trial NCT03203239?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03203239 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03203239's enrollment target sits among peer trials
40 29th of 50 higher than 20 of 50 other Peripheral Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
RECRUITING · NA
-
BEETroot Juice to Reverse Functional Impairment in PAD
RECRUITING · NA
-
Telehealth Delivered Home-based Walking for Vets With Peripheral Artery Disease
RECRUITING · NA
-
The THOR IDE Study
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
-
Leg Heat Therapy in Peripheral Artery Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI